{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:21:19Z","timestamp":1790673679719,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00280-021-04288-0","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T05:03:02Z","timestamp":1621659782000},"page":"379-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0104-5396","authenticated-orcid":false,"given":"Rachael","family":"Lawson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9773-6580","authenticated-orcid":false,"given":"Lachlan","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-3711","authenticated-orcid":false,"given":"Stefanie","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"issue":"5","key":"4288_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","volume":"15","author":"SO Ciurea","year":"2009","unstructured":"Ciurea SO, Andersson BS (2009) Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(5):523\u2013536. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.489","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4288_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/1389200215666140202214012","volume":"15","author":"P Huezo-Diaz","year":"2014","unstructured":"Huezo-Diaz P, Uppugunduri CR, Tyagi AK, Krajinovic M, Ansari M (2014) Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children. Curr Drug Metab 15(3):251\u2013264","journal-title":"Curr Drug Metab"},{"key":"4288_CR3","unstructured":"Otsuka Australia Pharmaceutical Pty Ltd. Australian Product Information Busulfex (Busulfan) Injection. eMIMs2018. pp 1\u201321"},{"issue":"2","key":"4288_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","volume":"15","author":"IH Bartelink","year":"2009","unstructured":"Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA et al (2009) Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 15(2):231\u2013241. https:\/\/doi.org\/10.1016\/j.bbmt.2008.11.022","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"4288_CR5","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/s2352-3026(16)30114-4","volume":"3","author":"IH Bartelink","year":"2016","unstructured":"Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J et al (2016) Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol 3(11):e526\u2013e536. https:\/\/doi.org\/10.1016\/s2352-3026(16)30114-4","journal-title":"Lancet Haematol"},{"issue":"3","key":"4288_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.bmt.1703612","volume":"30","author":"JS McCune","year":"2002","unstructured":"McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR et al (2002) Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 30(3):167\u2013173. https:\/\/doi.org\/10.1038\/sj.bmt.1703612","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"4288_CR7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.bmt.1703264","volume":"28","author":"AM Bolinger","year":"2001","unstructured":"Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV et al (2001) Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 28(11):1013\u20131018. https:\/\/doi.org\/10.1038\/sj.bmt.1703264","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4288_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/sj.bmt.1703207","volume":"28","author":"N Bleyzac","year":"2001","unstructured":"Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y et al (2001) Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 28(8):743\u2013751. https:\/\/doi.org\/10.1038\/sj.bmt.1703207","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4288_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2125.1999.00971.x","volume":"48","author":"NH Holford","year":"1999","unstructured":"Holford NH (1999) Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 48(1):9\u201313","journal-title":"Br J Clin Pharmacol"},{"key":"4288_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14434","author":"N Holford","year":"2020","unstructured":"Holford N, Ma GD, Metz D (2020) TDM is dead. Long live TCI!. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.14434","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"4288_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40262-020-00877-z","volume":"59","author":"H Marsit","year":"2020","unstructured":"Marsit H, Philippe M, Neely M, Rushing T, Bertrand Y, Ducher M et al (2020) Intra-individual pharmacokinetic variability of intravenous busulfan in hematopoietic stem cell-transplanted children. Clin Pharmacokinet 59(8):1049\u20131061. https:\/\/doi.org\/10.1007\/s40262-020-00877-z","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4288_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/FTD.0b013e31826051bb","volume":"34","author":"IH Bartelink","year":"2012","unstructured":"Bartelink IH, van Kesteren C, Boelens JJ, Egberts TC, Bierings MB, Cuvelier GD et al (2012) Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit 34(5):574\u2013583. https:\/\/doi.org\/10.1097\/FTD.0b013e31826051bb","journal-title":"Ther Drug Monit"},{"issue":"3","key":"4288_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/1078-0432.Ccr-13-1960","volume":"20","author":"JS McCune","year":"2014","unstructured":"McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH (2014) Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res 20(3):754\u2013763. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-1960","journal-title":"Clin Cancer Res"},{"issue":"21","key":"4288_CR14","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1158\/1078-0432.CCR-11-0074","volume":"17","author":"MN Trame","year":"2011","unstructured":"Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G (2011) Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res 17(21):6867\u20136877. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0074","journal-title":"Clin Cancer Res"},{"issue":"16","key":"4288_CR15","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.ejca.2012.05.020","volume":"48","author":"GJ Veal","year":"2012","unstructured":"Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D et al (2012) Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1\/SIOPEN trial. Eur J Cancer 48(16):3063\u20133072. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.020","journal-title":"Eur J Cancer"},{"issue":"2","key":"4288_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","volume":"37","author":"JR Long-Boyle","year":"2015","unstructured":"Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D et al (2015) Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit 37(2):236\u2013245","journal-title":"Ther Drug Monit"},{"issue":"6","key":"4288_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/BF00257448","volume":"24","author":"G Vassal","year":"1989","unstructured":"Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J (1989) Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 24(6):386\u2013390","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4288_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/bmt.2015.218","volume":"51","author":"M Philippe","year":"2016","unstructured":"Philippe M, Goutelle S, Guitton J, Fonrose X, Bergeron C, Girard P et al (2016) Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children. Bone Marrow Transplant 51(1):72\u201378. https:\/\/doi.org\/10.1038\/bmt.2015.218","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"4288_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/bmt.2009.143","volume":"45","author":"M Ansari","year":"2010","unstructured":"Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Theoret Y, Champagne MA et al (2010) Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant 45(2):261\u2013267. https:\/\/doi.org\/10.1038\/bmt.2009.143","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"4288_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","volume":"51","author":"IH Bartelink","year":"2012","unstructured":"Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB et al (2012) Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet 51(5):331\u2013345. https:\/\/doi.org\/10.2165\/11598180-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4288_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/0091270006295789","volume":"47","author":"BP Booth","year":"2007","unstructured":"Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D et al (2007) Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 47(1):101\u2013111. https:\/\/doi.org\/10.1177\/0091270006295789","journal-title":"J Clin Pharmacol"},{"issue":"14","key":"4288_CR22","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2217\/pgs.13.159","volume":"14","author":"MH ten Brink","year":"2013","unstructured":"ten Brink MH, van Bavel T, Swen JJ, van der Straaten T, Bredius RG, Lankester AC et al (2013) Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics 14(14):1683\u20131690. https:\/\/doi.org\/10.2217\/pgs.13.159","journal-title":"Pharmacogenomics"},{"issue":"7","key":"4288_CR23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/bcp.13566","volume":"84","author":"T Nava","year":"2018","unstructured":"Nava T, Kassir N, Rezgui MA, Uppugunduri CRS, Huezo-Diaz Curtis P, Duval M et al (2018) Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. Br J Clin Pharmacol 84(7):1494\u20131504. https:\/\/doi.org\/10.1111\/bcp.13566","journal-title":"Br J Clin Pharmacol"},{"key":"4288_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00947-2","author":"R Lawson","year":"2020","unstructured":"Lawson R, Staatz CE, Fraser CJ, Hennig S (2020) Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-020-00947-2","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"4288_CR25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.bbmt.2011.11.025","volume":"18","author":"JW Lee","year":"2012","unstructured":"Lee JW, Kang HJ, Lee SH, Yu KS, Kim NH, Yuk YJ et al (2012) Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant 18(6):944\u2013950. https:\/\/doi.org\/10.1016\/j.bbmt.2011.11.025","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4288_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/0091270012447196","volume":"53","author":"JS McCune","year":"2013","unstructured":"McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC et al (2013) Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol 53(3):264\u2013275. https:\/\/doi.org\/10.1177\/0091270012447196","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"4288_CR27","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbmt.2013.08.014","volume":"19","author":"RM Savic","year":"2013","unstructured":"Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH et al (2013) Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 19(11):1608\u20131614. https:\/\/doi.org\/10.1016\/j.bbmt.2013.08.014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4288_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/ftd.0000000000000276","volume":"38","author":"M Neely","year":"2016","unstructured":"Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D et al (2016) Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the Bestdose software. Ther Drug Monit 38(3):332\u2013342. https:\/\/doi.org\/10.1097\/ftd.0000000000000276","journal-title":"Ther Drug Monit"},{"issue":"3","key":"4288_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cpt1979263294","volume":"26","author":"LB Sheiner","year":"1979","unstructured":"Sheiner LB, Beal S, Rosenberg B, Marathe VV (1979) Forecasting individual pharmacokinetics. Clin Pharmacol Ther 26(3):294\u2013305","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"4288_CR30","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1128\/AAC.01131-16","volume":"60","author":"MA Barras","year":"2016","unstructured":"Barras MA, Serisier D, Hennig S, Jess K, Norris RL (2016) Bayesian estimation of tobramycin exposure in patients with cystic fibrosis. Antimicrob Agents Chemother 60(11):6698\u20136702. https:\/\/doi.org\/10.1128\/AAC.01131-16","journal-title":"Antimicrob Agents Chemother"},{"key":"4288_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0610-9","author":"M Burgard","year":"2017","unstructured":"Burgard M, Sandaradura I, van Hal SJ, Stacey S, Hennig S (2017) Evaluation of tobramycin exposure predictions in three Bayesian forecasting programmes compared with current clinical practice in children and adults with cystic fibrosis. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-017-0610-9","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4288_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40262-018-0707-9","volume":"58","author":"Y Gao","year":"2019","unstructured":"Gao Y, Hennig S, Barras M (2019) Monitoring of tobramycin exposure: what is the best estimation method and sampling time for clinical practice? Clin Pharmacokinet 58(3):389\u2013399. https:\/\/doi.org\/10.1007\/s40262-018-0707-9","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4288_CR33","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","volume":"99","author":"E Storset","year":"2015","unstructured":"Storset E, Asberg A, Skauby M, Neely M, Bergan S, Bremer S et al (2015) Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients\u2014a prospective, randomized study. Transplantation 99(10):2158\u20132166. https:\/\/doi.org\/10.1097\/TP.0000000000000708","journal-title":"Transplantation"},{"issue":"5","key":"4288_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/jphp.12709","volume":"69","author":"B Al-Metwali","year":"2017","unstructured":"Al-Metwali B, Mulla H (2017) Personalised dosing of medicines for children. J Pharm Pharmacol 69(5):514\u2013524. https:\/\/doi.org\/10.1111\/jphp.12709","journal-title":"J Pharm Pharmacol"},{"key":"4288_CR35","unstructured":"Holford NH, Holford S. NextDose\u2014a web based dosing tool\u2014development version 2017. PAGANZ, Adelaide, Australia. https:\/\/www.paganz.org\/abstracts\/nextdose-a-web-based-dosing-tool-development-version-2017\/2017."},{"key":"4288_CR36","unstructured":"Jelliffe RW (1991) The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic\/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care 922\u2013924"},{"key":"4288_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fphar.2020.00888","volume":"2020","author":"P Shukla","year":"2020","unstructured":"Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC et al (2020) Assessment of a model-informed precision dosing platform use in routine clinical care for personalized busulfan therapy in the pediatric hematopoietic cell transplantation (HCT) population. Front Pharmacol 2020:11. https:\/\/doi.org\/10.3389\/fphar.2020.00888","journal-title":"Front Pharmacol"},{"key":"4288_CR38","unstructured":"Apotex Pty Ltd Australia (2018) Busulfan APOTEX injection product information Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2014-PI-03287-1&d=2018042316114622483"},{"key":"4288_CR39","unstructured":"Otsuka America Pharmaceutical I (2015) Busulfex (busulfan) for injection. Food and Drug Administration. 01\/2015 ed2015"},{"key":"4288_CR40","unstructured":"Pierre Fabre Medicament (2017) Busilvex: EPAR-product information. European Medicines Agency, pp 1\u201340"},{"issue":"10","key":"4288_CR41","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/bcp.13982","volume":"85","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhou F, Qi H, Ni H, Hu Q, Zhou C et al (2019) Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. Br J Clin Pharmacol 85(10):2292\u20132301. https:\/\/doi.org\/10.1111\/bcp.13982","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4288_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.bbmt.2008.03.002","volume":"14","author":"LL Dupuis","year":"2008","unstructured":"Dupuis LL, Sibbald C, Schechter T, Ansari M, Gassas A, Th\u00e9or\u00eat Y et al (2008) IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transplant 14(5):576\u2013582. https:\/\/doi.org\/10.1016\/j.bbmt.2008.03.002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"4288_CR43","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ajh.24734","volume":"92","author":"SJ Rhee","year":"2017","unstructured":"Rhee SJ, Lee JW, Yu KS, Hong KT, Choi JY, Hong CR et al (2017) Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. Am J Hematol 92(7):607\u2013613. https:\/\/doi.org\/10.1002\/ajh.24734","journal-title":"Am J Hematol"},{"issue":"3","key":"4288_CR44","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/S2352-3026(17)30018-2","volume":"4","author":"IH Bartelink","year":"2017","unstructured":"Bartelink IH, Lalmohamed A, Long-Boyle JR, Boelens JJ (2017) Busulfan after HSCT in children and young adults\u2014authors\u2019 reply. Lancet Haematol 4(3):e103\u2013e104. https:\/\/doi.org\/10.1016\/S2352-3026(17)30018-2","journal-title":"Lancet Haematol"},{"issue":"3","key":"4288_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0009-9236(97)90160-0","volume":"61","author":"LB Sheiner","year":"1997","unstructured":"Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61(3):275\u2013291","journal-title":"Clin Pharmacol Ther"},{"key":"4288_CR46","volume-title":"Assessment of a model-based clinical decision support tool for busulfan in the pediatric hematopoietic cell transplantation population PI-138","year":"2018","unstructured":"Shukla P, Goswami S, Keizer RJ, Mangat R, Long-Boyle J (eds) (2018) Assessment of a model-based clinical decision support tool for busulfan in the pediatric hematopoietic cell transplantation population PI-138. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, USA"},{"key":"4288_CR47","unstructured":"Wicha S, Hennig S (2018) Handling inter-occasion variability in model implementation for Bayesian forecasting: a comparison of methods and metrics. In: Population approach group in Europe (PAGE) conference, Montreux, Switzerland (Abstract)"},{"issue":"6","key":"4288_CR48","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bcp.13901","volume":"85","author":"JA Abrantes","year":"2019","unstructured":"Abrantes JA, Jonsson S, Karlsson MO, Nielsen EI (2019) Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. Br J Clin Pharmacol 85(6):1326\u20131336. https:\/\/doi.org\/10.1111\/bcp.13901","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"4288_CR49","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00228-014-1680-3","volume":"70","author":"L Nezic","year":"2014","unstructured":"Nezic L, Derungs A, Bruggisser M, Tschudin-Sutter S, Krahenbuhl S, Haschke M (2014) Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy. Eur J Clin Pharmacol 70(7):829\u2013837. https:\/\/doi.org\/10.1007\/s00228-014-1680-3","journal-title":"Eur J Clin Pharmacol"},{"key":"4288_CR50","doi-asserted-by":"publisher","unstructured":"Kantasiripitak W, Van Daele R, Gijsen M, Ferrante M, Spriet I, Dreesen E (2020) Software tools for model-informed precision dosing: how well do they satisfy the needs? Front Pharmacol 11. https:\/\/doi.org\/10.3389\/fphar.2020.00620.","DOI":"10.3389\/fphar.2020.00620"},{"issue":"10","key":"4288_CR51","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/bcp.14066","volume":"85","author":"ZA Kumar","year":"2019","unstructured":"Kumar ZA, Burgard M, Stacey S, Sandaradura I, Lai T, Coorey C et al (2019) An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting. Br J Clin Pharmacol 85(10):2436\u20132441. https:\/\/doi.org\/10.1111\/bcp.14066","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04288-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04288-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04288-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T08:04:45Z","timestamp":1627373085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04288-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["4288"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04288-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No parties involved in the preparation of this manuscript have any conflicts of interests to declare, financial or otherwise.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}